Posted inClinical Updates Hematology-Oncology
Harnessing CD4+ T Cells: A New Frontier in Targeted Immunotherapy for ALK-Positive T-Cell Lymphoma
This article delineates the pivotal role of CD4+ T cells in mediating immune responses against ALK-positive anaplastic large cell lymphoma, highlighting preclinical evidence supporting immune checkpoint inhibitors as a promising therapeutic strategy.
